<DOC>
	<DOCNO>NCT00006379</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy use kill cancer cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy follow peripheral stem cell transplantation treat patient hematologic cancer aplastic anemia .</brief_summary>
	<brief_title>Non-Ablative Allo HSCT For Hematologic Malignancies SAA</brief_title>
	<detailed_description>OBJECTIVES : - Determine rate durable full donor hematologic engraftment patient high-risk hematologic malignancy severe aplastic anemia treat non-myeloablative conditioning use fludarabine , cyclophosphamide , anti-thymocyte globulin follow allogeneic peripheral blood stem cell transplantation . - Determine acute delay toxic effect non-myeloablative condition regimen patient population . - Determine event-free overall survival patient treat regimen . - Determine incidence severity acute chronic graft-versus-host disease patient treat regimen . - Determine rate quality immune reconstitution patient treat regimen . - Determine rate disease relapse incidence post-transplantation lymphoproliferative disease patient . OUTLINE : Patients stratify accord disease category ( malignant v non-malignant ) graft source ( unrelated v HLA-matched sibling ) . Beginning least 4 week conventional-dose chemotherapy , patient receive non-myeloablative conditioning comprise fludarabine IV 30 minute day -8 -4 , cyclophosphamide IV 2 hour day -3 -2 , anti-thymocyte globulin IV least 4 hour day -2 -1 . Patients undergo filgrastim ( G-CSF ) -mobilized allogeneic peripheral blood stem cell transplantation day 0 . Patients follow weekly 3 month , every 2 week 3 month , monthly 6 month , every 2 month thereafter . PROJECTED ACCRUAL : A minimum 30 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven highrisk hematologic malignancy Acute nonlymphocytic leukemia ( ANLL ) induction failure , first complete remission ( CR ) highrisk feature , include follow : Stem cell biphenotypic classification ( AMLM0 ) Erythroleukemia ( AMLM6 ) Acute megakaryocytic leukemia ( AMLM7 ) Cytogenetic marker indicative poor prognosis Failure achieve CR standard induction therapy Acute lymphocytic leukemia ( ALL ) ANLL relapse second subsequent remission Chronic myelogenous leukemia ( CML ) chronic accelerate phase Patients CML blast crisis eligible reinduction chemotherapy place chronic phase Highrisk ALL first CR high risk define presence ( 4 ; 11 ) , ( 9 ; 22 ) translocation , hyperleukocytosis ( initial WBC great 30,000/mm^3 ) , failure achieve CR day 28 standard induction No Tcell ALL ( 8 ; 14 ) positive Bcell ALL first remission hyperleukocytosis Myelodysplastic syndrome peripheral blood smear bone marrow examination Refractory medical management OR Cytogenetic abnormality predictive transformation acute leukemia include 5q , 7q , monosomy 7 , trisomy 8 OR Evidence evolution AML ( e.g. , refractory anemia excess blast ( RAEB ) RAEB transformation ) Multiple myeloma , nonHodgkin 's lymphoma ( NHL ) , ANLL , ALL recurrent disease autologous stem cell transplantation ( SCT ) At least 3 month since prior autologous SCT Hodgkin 's lymphoma , NHL , multiple myeloma beyond first CR primary induction failure whose disease demonstrate sensitivity pretransplantation cytoreduction ( define great 50 % reduction tumor burden ) Mantle zone NHL allow induction therapy Myeloproliferative disorder nonresponsive medical management require allografting , unless evidence grade 3 bad myelofibrosis marrow biopsy OR Histologically proven acquire severe aplastic anemia ( SAA ) recurrent unresponsive antithymocyte globulin and/or cyclosporine SAA define least 2 follow condition : Granulocyte count le 500/mm^3 Platelet count le 20,000/mm^3 Absolute reticulocyte count le 20,000/mm^3 correction hematocrit Ineligible full ablative conditioning due follow condition : Prior extensive therapy ( 2 salvage chemotherapy regimens and/or autologous transplantation ) Over age 55 OR Under age 55 comorbid disease ( e.g. , suboptimal cardiac , pulmonary , renal function and/or prior lifethreatening infection ) HLAA , B , DR phenotypically identical sibling donor OR HLAA , B , DR identical genetically match unrelated donor No ANLL first CR ( less 5 % blast marrow ) translocation ( 8 ; 21 ) inv ( 16 ) unless fail firstline induction therapy OR No ANLL first CR ( less 5 % blast marrow ) translocation ( 15 ; 17 ) abnormality unless fail firstline induction therapy OR molecular evidence persistent disease No active CNS disease PATIENT CHARACTERISTICS : Age : 0 70 Performance status : Zubrod 01 Karnofsky 80100 % Life expectancy : At least 3 month Hematopoietic : See Disease Characteristics Hepatic : ALT/AST great 4 time normal Bilirubin great 2.0 mg/dL Renal : See Disease Characteristics Creatinine clearance least 50 mL/min Cardiovascular : See Disease Characteristics Shortening fraction ejection fraction least 40 % normal age echocardiogram radionuclide scan No clinically significant comorbid illness ( e.g. , myocardial infarction cerebrovascular accident ) Pulmonary : See Disease Characteristics FVC FEV_1 least 60 % predict age DLCO least 60 % predict adult Other : No severe neurosensory symptom ( i.e. , peripheral neuropathy ) HIV negative Active infection allow controlled appropriate drug therapy Not pregnant nursing Negative pregnancy test PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : Recovered prior therapy No concurrent investigational agent unless approve protocol investigator</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>monoclonal gammopathy undetermined significance</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>isolated plasmacytoma bone</keyword>
	<keyword>extramedullary plasmacytoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>chronic idiopathic myelofibrosis</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>childhood acute erythroleukemia ( M6 )</keyword>
	<keyword>childhood acute megakaryocytic leukemia ( M7 )</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>primary systemic amyloidosis</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>childhood acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>